TOP2A Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Regulated by MiR-144-3p

Overview

Journal J Cancer

Specialty Oncology

Date 2022 Jan 24

PMID 35069905

Authors

Tao Wang

Jing Lu

Rangrang Wang

Wanyue Cao

Junming Xu

Affiliations

Soon will be listed here.

Abstract

Topoisomerase II alpha (TOP2A) is an important nuclear protein which is found in various types of cancers. Whether TOP2A plays an important role in hepatocellular carcinoma (HCC) remains unclear. Through bioinformatic analysis and clinical specimen verification, we found that TOP2A is highly expressed in HCC and is associated with poor prognosis. Knockdown and overexpression of TOP2A can respectively inhibit or promote proliferation, metastasis and invasion of HCC cells and . Mechanismly, TOP2A activates cell cycle progression from G2 to M phase by inhibiting the phosphorylation of CHK1 and promotes Epithelial-to-mesenchymal transition (EMT) process. We further confirmed that TOP2A is a direct target of miR-144-3p whose overexpressing can partially reverse the effect of TOP2A in HCC cells. Our data suggested that TOP2A functions by promoting the proliferation, migration, invasion and EMT process of HCC and can be considered as a potential target for the treatment of HCC.

Citing Articles

Interpretable single-cell factor decomposition using sciRED.

Pouyabahar D, Andrews T, Bader G Nat Commun. 2025; 16(1):1878.

PMID: 39987196 PMC: 11846867. DOI: 10.1038/s41467-025-57157-2.

Computational screening and molecular dynamics of natural compounds targeting the SH2 domain of STAT3: a multitarget approach using network pharmacology.

Kumar S, Kumar B, Nayak R, Pandey S, Kumar N, Pai K Mol Divers. 2025; .

PMID: 39786519 DOI: 10.1007/s11030-024-11075-5.

Lnc-EST885 promotes hepatocellular carcinoma metastasis through PI3K / AKT pathway by interaction with TRAF4.

Zhu S, Wang G, Zhang Y, Zou M, Li Z, Qu S Transl Oncol. 2024; 52():102254.

PMID: 39721246 PMC: 11732567. DOI: 10.1016/j.tranon.2024.102254.

Advances in research on malignant tumors and targeted agents for TOP2A (Review).

Zhou T, Niu Y, Li Y Mol Med Rep. 2024; 31(2).

PMID: 39670307 PMC: 11653171. DOI: 10.3892/mmr.2024.13415.

Overexpression of , and Genes Could Be an Important Clue for Luminal A Breast Cancer.

Kaya M, Abuaisha A, Suer I, Alptekin M, Abanoz F, Emiroglu S Eur J Breast Health. 2024; 20(4):284-291.

PMID: 39323324 PMC: 11589183. DOI: 10.4274/ejbh.galenos.2024.2024-4-3.

References

Jain M, Zhang L, He M, Zhang Y, Shen M, Kebebew E . TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013; 20(3):361-70. PMC: 4990817. DOI: 10.1530/ERC-12-0403. View

Rimassa L, Pressiani T, Merle P . Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer. 2019; 8(6):427-446. PMC: 6883446. DOI: 10.1159/000499765. View

Lu T, Rothenberg M . MicroRNA. J Allergy Clin Immunol. 2017; 141(4):1202-1207. PMC: 5889965. DOI: 10.1016/j.jaci.2017.08.034. View

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

Lan J, Huang H, Lee S, Chen T, Tai H, Hsu H . TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumour Biol. 2013; 35(1):179-87. DOI: 10.1007/s13277-013-1022-6. View

Yin Y, Liu H, Xu J, Shi D, Zhai L, Liu B . miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2. Oncol Rep. 2018; 40(6):3479-3488. DOI: 10.3892/or.2018.6772. View

Nielsen K, Muller S, Moller S, Schonau A, Balslev E, Knoop A . Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol. 2009; 4(2):161-8. PMC: 5527893. DOI: 10.1016/j.molonc.2009.11.001. View

Grandhi M, Kim A, Ronnekleiv-Kelly S, Kamel I, Ghasebeh M, Pawlik T . Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016; 25(2):74-85. DOI: 10.1016/j.suronc.2016.03.002. View

Niotis A, Tsiambas E, P Fotiades P, Ragos V, Polymeneas G . ki-67 and Topoisomerase IIa proliferation markers in colon adenocarcinoma. J BUON. 2019; 23(7):24-27. View

10.

Heestand G, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R . Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 2017; 83:80-87. PMC: 5613945. DOI: 10.1016/j.ejca.2017.06.019. View

11.

Liu T, Zhang H, Yi S, Gu L, Zhou M . Mutual regulation of MDM4 and TOP2A in cancer cell proliferation. Mol Oncol. 2019; 13(5):1047-1058. PMC: 6487731. DOI: 10.1002/1878-0261.12457. View

12.

Kanwal F, Singal A . Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology. 2019; 157(1):54-64. PMC: 6636644. DOI: 10.1053/j.gastro.2019.02.049. View

13.

Bax B, Chan P, Eggleston D, Fosberry A, Gentry D, Gorrec F . Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010; 466(7309):935-40. DOI: 10.1038/nature09197. View

14.

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

15.

Xiao W, Lou N, Ruan H, Bao L, Xiong Z, Yuan C . Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A. Cell Physiol Biochem. 2017; 43(6):2420-2433. DOI: 10.1159/000484395. View

16.

Forner A, Gilabert M, Bruix J, Raoul J . Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2014; 12(1):10. DOI: 10.1038/nrclinonc.2014.122-c2. View

17.

Zhang D, Li Z, Li T, Luo D, Feng X, Liu Y . miR-517a promotes Warburg effect in HCC by directly targeting FBP1. Onco Targets Ther. 2018; 11:8025-8032. PMC: 6239112. DOI: 10.2147/OTT.S172084. View

18.

Chen T, Sun Y, Ji P, Kopetz S, Zhang W . Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. 2014; 34(31):4019-31. PMC: 4404185. DOI: 10.1038/onc.2014.332. View

19.

Kourtidis A, Lu R, Pence L, Anastasiadis P . A central role for cadherin signaling in cancer. Exp Cell Res. 2017; 358(1):78-85. PMC: 5544584. DOI: 10.1016/j.yexcr.2017.04.006. View

20.

Meng H, Chen R, Li W, Xu L, Xu L . Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Pathol Int. 2012; 62(6):391-9. DOI: 10.1111/j.1440-1827.2012.02808.x. View